APA-Zitierstil (7. Ausg.)

Radujković, A., Boch, T., Nolte, F., Nowak, D., Kunz, C., Gieffers, A., . . . Luft, T. (2020). Clinical response to the CD95-ligand inhibitor asunercept is defined by a pro-inflammatory serum cytokine profile. Cancers, 13(4), . https://doi.org/10.3390/cancers12123683

Chicago-Zitierstil (17. Ausg.)

Radujković, Aleksandar, et al. "Clinical Response to the CD95-ligand Inhibitor Asunercept Is Defined by a Pro-inflammatory Serum Cytokine Profile." Cancers 13, no. 4 (2020). https://doi.org/10.3390/cancers12123683.

MLA-Zitierstil (9. Ausg.)

Radujković, Aleksandar, et al. "Clinical Response to the CD95-ligand Inhibitor Asunercept Is Defined by a Pro-inflammatory Serum Cytokine Profile." Cancers, vol. 13, no. 4, 2020, https://doi.org/10.3390/cancers12123683.